- Case report
- Open Access
- Open Peer Review
Cardiogenic shock following administration of propofol and fentanyl in a healthy woman: a case report
© Renilla et al; licensee BioMed Central Ltd. 2011
- Received: 14 February 2011
- Accepted: 16 August 2011
- Published: 16 August 2011
Cardiogenic shock is very uncommon in healthy people. The differential diagnosis for patients with acute heart failure in previously healthy hearts includes acute myocardial infarction and myocarditis. However, many drugs can also depress myocardial function. Propofol and fentanyl are frequently used during different medical procedures. The cardiovascular depressive effect of both drugs has been well established, but the development of cardiogenic shock is very rare when these agents are used.
After a minor surgical intervention, a 32-year-old Caucasian woman with no significant medical history went into sudden hemodynamic deterioration due to acute heart failure. An urgent echocardiogram showed severe biventricular dysfunction and an estimated left ventricular ejection fraction of 20%. Extracorporeal life support and mechanical ventilation were required. Five days later her ventricular function had fully recovered, which allowed the progressive withdrawal of medical treatment. Prior to her hospital discharge, cardiac MRI showed neither edema nor pathological deposits on the delayed contrast enhancement sequences. At her six-month follow-up examination, the patient was asymptomatic and did not require treatment.
Although there are many causes of cardiogenic shock, the presence of abrupt hemodynamic deterioration and the absence of a clear cause could be related to the use of propofol and fentanyl.
- Left Ventricular Ejection Fraction
- Cardiogenic Shock
- Acute Heart Failure
Cardiogenic shock is the most serious form of presentation of heart failure (HF). The anticipation of hemodynamic deterioration and multiple organ failure in these patients is very important in terms of survival. The outcome for patients with refractory acute cardiogenic shock remains disproportionately poor. Technological advances in recent years have enabled the development of new treatments, such as extracorporeal life support (ELS). ELS is a variation of cardiopulmonary bypass which could improve the outcomes of patients in cardiogenic shock . Although ischemic heart disease is the most common cause, there are many other etiologies . Some drugs commonly used for sedation and analgesia during surgical procedures, as frequently as electrical cardioversion or transesophageal echocardiography, may have undesirable effects on cardiac hemodynamics. Propofol and fentanyl could depress myocardial function, but the effect of these agents on left ventricular ejection fraction (LVEF) in patients with normal left ventricle function has been reported to be mildly reduced [3, 4]. The development of cardiogenic shock in patients treated with these drugs is a very uncommon situation.
To establish the causal diagnosis of HF, it is necessary to determine whether the clinical presentation is a de novo process or a chronic entity exacerbated by surgery. In our patient, the absence of ventricular remodeling visualized by TTE suggests the former postulate. Regarding its etiology, many possibilities should be taken into account. Post-partum cardiomyopathy usually develops in late pregnancy or during the first months after delivery . In our patient, childbirth was very unlikely the cause of her acute HF as delivery had occurred two years before. A viral infection could justify the clinical context of acute myocarditis , but her sudden clinical deterioration, with no history of infection or negative serologies and lack of typical findings on MRI, makes this diagnosis unlikely. Propofol infusion syndrome includes arrhythmias, hemodynamic deterioration, metabolic acidosis, rhabdomyolysis, and impaired renal and hepatic function. This clinical entity has been described mainly in pediatric critical care patients and has been associated with prolonged use (>48 hours) and high doses (>4 mg/kg/hour) . Ondansetron is a 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist used mainly as an anti-emetic. Although considered a safe class of medications by many clinicians, several of the 5-HT3 receptor antagonists have been associated with adverse cardiovascular effects . There is a rare possibility of convulsions, chest pain, arrhythmias, hypotension, or bradycardia associated with using ondansetron, but we have not found any case in the literature describing a connection between the use of this drug in the post-operative and the development of HF. Takotsubo cardiomyopathy (TTC) is an acute cardiac syndrome mimicking elevated ST-segment myocardial infarction characterized by transient regional wall motion abnormalities involving the apical and middle portions of the left ventricle in the absence of significant obstructive coronary disease . Recently, an apical sparing variant defined as akinesia of the basal and middle segments of all walls has been described . In our patient, the absence of electrocardiographic and echocardiographic alterations suggestive of TTC leads us to reject this diagnostic possibility. The association of propofol and fentanyl as a cause of severe, acute HF has been described previously . Other than the case described by Chow et al. , however, we have not found another case report in the literature that mentions the combination of these drugs as a cause of severe, acute HF due to ventricular dysfunction in patients with healthy hearts. In this regard, both propofol and fentanyl may cause depression of ventricular function and decreased blood pressure. Propofol dilates the arteries by inducing nitric oxide synthesis, blocks calcium channels, and activates protein kinase C, all of which, taken together, lead to a decrease in pre-load and a decline in cardiac output. Apart from this possibility, an intrinsic negative inotropic effect attributable to propofol itself has also been reported [4, 12]. This effect is dose-dependent . It occurs most often when used in combination with fentanyl and in patients with or without previous heart disease . Both mechanisms might trigger a state of cardiogenic shock in patients with individual susceptibility. When these agents are used in combination, additional precautions should be taken in all patients, including those with normal left ventricular function. Because of refractory cardiogenic shock, ELS was needed in our patient. ELS should be considered in patients with severe, life-threatening respiratory or cardiac failure that does not respond to conventional intensive care management . Currently, several options are available for circulatory support, including surgically implanted ventricular assistance devices, percutaneous assistance devices, and ECMO . In our case, ECMO provided reasonable short-term support, allowing the patient to recover from multi-organ injury and increasing the time to complete a transplant evaluation if necessary. The use of this device is a support modality rather than a treatment in itself. As it requires well-trained personnel and is not without risk, selection of patients in whom this device can be used is required. So, the disease process must be reversible, or, failing this, the patient should be a candidate for transplantation or insertion of a ventricular assistance device.
In conclusion, the final etiological diagnosis of our patient is uncertain. Her severe, acute hemodynamic deterioration due to acute heart failure seems to have been causally related to some event that occurred during the peri-operative period. Propofol and fentanyl are often used during different medical procedures. The effects previously described, although uncommon, should be taken into account in cases of abrupt hemodynamic deterioration and an absence of other possible causes. ECMO is an effective salvage strategy for the treatment of patients with extreme hemodynamic instability and multi-organ injury due to acute HF.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Gaffney AM, Wildhirt SM, Griffin MJ, Annich GM, Radomski MW: Extracorporeal life support. BMJ. 2010, 341: c5317-10.1136/bmj.c5317.View ArticlePubMedGoogle Scholar
- Topalian S, Ginsberg F, Parrillo JE: Cardiogenic shock. Crit Care Med. 2008, 36: S66-S74. 10.1097/01.CCM.0000296268.57993.90.View ArticlePubMedGoogle Scholar
- Lepage JY, Pinaud ML, Hélias JH, Juge CM, Cozian AY, Farinotti R, Souron RJ: Left ventricular function during propofol and fentanyl anesthesia in patients with coronary artery disease: assessment with a radionuclide approach. Anesth Analg. 1988, 67: 949-955.PubMedGoogle Scholar
- Larsen JR, Torp P, Norrild K, Sloth E: Propofol reduces tissue-Doppler markers of left ventricle function: a transthoracic echocardiographic study. Br J Anaesth. 2007, 98: 183-188. 10.1093/bja/ael345.View ArticlePubMedGoogle Scholar
- Abboud J, Murad Y, Chen-Scarabelli C, Saravolatz L, Scarabelli TM: Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007, 118: 295-303. 10.1016/j.ijcard.2006.08.005.View ArticlePubMedGoogle Scholar
- Magnani JW, Dec GW: Myocarditis: current trends in diagnosis and treatment. Circulation. 2006, 113: 876-890. 10.1161/CIRCULATIONAHA.105.584532.View ArticlePubMedGoogle Scholar
- Fodale V, La Monaca E: Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf. 2008, 31: 293-303. 10.2165/00002018-200831040-00003.View ArticlePubMedGoogle Scholar
- Havrilla PL, Kane-Gill SL, Verrico MM, Seybert AL, Reis SE: Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother. 2009, 43: 532-536. 10.1345/aph.1L544.View ArticlePubMedGoogle Scholar
- Pilgrim TM, Wyss TR: Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: a systematic review. Int J Cardiol. 2008, 124: 283-292. 10.1016/j.ijcard.2007.07.002.View ArticlePubMedGoogle Scholar
- Hahn JY, Gwon HC, Park SW, Choi SH, Choi JH, Choi JO, Lee SC, On YK, Kim JS, Kim DK, Jeon ES, Lee SH, Hong KP, Park JE: The clinical features of transient left ventricular nonapical ballooning syndrome: comparison with apical ballooning syndrome. Am Heart J. 2007, 154: 1166-1173. 10.1016/j.ahj.2007.08.003.View ArticlePubMedGoogle Scholar
- Chow SL, Houseman D, Phung T, French WJ: Transient acute decompensated heart failure following propofol and fentanyl administration in a healthy 19-year-old patient. Congest Heart Fail. 2010, 16: 80-81. 10.1111/j.1751-7133.2009.00125.x.View ArticlePubMedGoogle Scholar
- Bermudez EA, Chen MH: Cardiac arrest associated with intravenous propofol during transesophageal echocardiography before DC cardioversion. Heart Dis. 2002, 4: 355-357. 10.1097/00132580-200211000-00004.View ArticlePubMedGoogle Scholar
- Krzych LJ, Szurlej D, Bochenek A: Rationale for propofol use in cardiac surgery. J Cardiothorac Vasc Anesth. 2009, 23: 878-885. 10.1053/j.jvca.2009.05.001.View ArticlePubMedGoogle Scholar
- Ziemba EA, John R: Mechanical circulatory support for bridge to decision: which device and when to decide. J Card Surg. 2010, 25: 425-433. 10.1111/j.1540-8191.2010.01038.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.